Canada markets open in 8 hours 48 minutes

Khiron Life Sciences Corp. (KHRN.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.4700-0.0500 (-9.62%)
At close: 3:59PM EDT
Sign in to post a message.
  • j
    Khiron Receives Accreditation for UK Medical Cannabis Education and Partners with UK's Cellen Therapeutics to Improve Clinician Education
    Download as PDFAPRIL 13, 2021 9:30AM EDT
    Company has received UK Continuing Professional Development ("CPD") accreditation for its global education platform, Khiron Academy
    UK medical professionals may now earn CPD credits through Khiron's medical cannabis education program
    The Company has entered into a strategic partnership with Cellen Therapeutics, a leader in digital healthcare in the UK, to increase patient access via medical cannabis education
    As a leading international medical cannabis educator, nearly 1,000 medical professionals in Latin America and the United Kingdom have registered for, or completed, Khiron Academy training
    TORONTO, April 13, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce it has received UK Continuing Professional Development ("CPD") accreditation for Khiron Academy, the Company's global medical cannabis education platform.

    Khiron has entered into a strategic partnership with Cellen Therapeutics, a leader in digital healthcare in the UK
    Additionally, following its accreditation, the Company has entered into a strategic partnership with Cellen Therapeutics, a leader in digital healthcare in the UK and fellow founding member of Project Twenty21, to increase patient access through medical cannabis education initially. Khiron Academy will be made available to prescribers in the UK that have registered with Cellen's MedCanHub, an emerging education portal. Cellen is market leader, widely recognized for also launching the UK's first digital pain clinic, Leva.

    Tejinder Virk, President of Khiron Europe, commented, "Over the last year, Khiron has seen a direct correlation between physician education and patient access. With Khiron Academy's CPD accreditation and through our strategic partnership with Cellen Therapeutics, we are positioned to reach a growing number of medical professionals, and in turn, provide patients with greater access to medical cannabis products."

    Eric Bystrom, CEO of Cellen commented, "We are pleased to be joining forces with Khiron on educating prescribing specialists in the UK. Khiron is a clear global leader in medical cannabis education. We share common values in improving patient lives by educating doctors and optimizing the standard of medical care. Our aim is to create a practical guide for responsibly prescribing patients with safe and efficacious medical cannabis products."

    In the UK, Khiron continues to leverage educational materials developed by the Company to train medical professionals in Latin America, along with clinical data from thousands of Khiron patients. In addition to Cellen's MedCanHub (accessible to medical professionals at, Khiron Academy is available to members of the Medical Cannabis Clinicians Society (MCCS) and core to the training of prescribing specialists for Project Twenty21, a 20,000-patient observational study backed Drug Science in UK.

    To date, the Company has trained nearly 1000 medical professionals in Latin America and the UK. Over the last year, physicians trained by Khiron in Latin America have issued over 13,000 prescriptions, with a compound monthly growth rate of nearly 50%. Khiron Academy will be a platform for sharing the Company's clinical expertise, in conjunction with clinical data arising from Khiron's wholly-owned clinics in LatAm.

    About Khiron Life Sciences Corp.
    Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America, and operational activity in Europe and North America. Khiron is the leading medical cannabis provider in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution and sales, and international export of both low and high THC medical cannabis products. The Company has filled medical cannabis prescriptions in Colombia, Peru, Germany and the United Kingdom, and is positioned to commence sales in Mexico, Germany and Brazil in 2021.

    Leveraging wholly-owned medical clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty. Its Wellbeing unit launched the first branded CBD skincare brand in Colombia, with KuidaTM now marketed in multiple jurisdictions in Latin America, the US and United Kingdom. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.
  • j
    Remember with all this political theater going on in Mexico over full legalization; medical use is already legal in Mexico as of early this year.
  • M
    Woah there's the dip into the .30s..
  • s
    This is going to five dollars by end of next year
  • Y
    One thing is for sure, it will get a lift when Mexico is official. The sector is no longer in the mood for 'nearly' or 'close', or 'soon'. It's clear that it wants a bill that has been signed, sealed, and delivered. So be it.
  • T
    Khiron Expands Product Offering in UK and Increases Patient Access
  • P
    A dilution is coming this summer. After that I'll buy Khiron again.
  • M
    Have they announced an earnings date? Can't seem to find an official announcement
  • R
    I will definitely expect a decent jump in share price once full legalization is passed ,But the real money for this stock will be in mergers and acquisitions . Look at Canada or US companies to acquire this stock for its cheap labour , all year outdoor grows and further access to South American customers . Cannabis is quickly becoming a world wide commodity you must own in some form
  • j
    were moving side ways after a big step up in price support; Mexico news hasn't even legalized officially; just wait tell its the new big story this month.
  • A
    just got alot more. lol
  • D
    Thank you Aphria for the cheap shares!
  • A
    Today they Confirmed that they are well positioned to enter the recreational market, and that It is not off the table once Legalization happens in Mexico. Current growth is based on Medical. They will keep adding clinics, 10 in Coming months. They offset their energy consumption with solar and their Board members are amazing. :)
  • E
    I love how people post on this board as if everyone bought in at the same price they did...LOL. I took advantage of the drop to the .20's and the sky is looking pretty blue to me...Petar I am sorry you are on the losing end but this is a Finance Board...not your relevant financial/company metric data that is value added or go elsewhere. As I have noted before, this is a great company with HUGE potential...if you don't like it...SELL. I for one would be perfectly content to see this company go to $1 and hold there...which it will when Mexico fully legalizes and Khiron announces entry into the market. Fox may be money hungry and greedy but he needs the stock to get above $2.0 for him to really make money so I am fairly sure it will get there eventually, at which point I cash out over $1M up
  • S
    Time to buy more!!
  • G
    Khiron Updates Zerenia™ Expansion Program; Announces Plans to Open Three Additional Satellite Clinics in Colombia by End of Q2
  • M
    mexico advances legislation past the second senate chamber. the third should be tomorrow with a good possibility a full house vote Thursday per marijuana moment article ... got more shares at lower prices not knowing about the article since I was busy! I'm at 100k plus shares now. hopefully get to add more if ppl keep this price depressed again!
  • M
    geez mexico might extend deadline again to legalize smh